代谢组学生物标志物与帕金森病进展强相关
该研究旨在发现帕金森病(PD)进展的生物标志物,对49例未用药的轻度PD患者(平均年龄61.4岁,平均病程11.4个月)在基线及最长24个月内两次采集血浆和脑脊液,用超高效液相色谱串联质谱检测小分子代谢物。期间UPDRS第2+3部分评分平均增加47%(从28.8到42.2)。LASSO从575种血浆和383种脑脊液生化物质中选出15种基线血浆成分,与UPDRS评分变化高度正相关(0.87,p=2.2e-16)。
要点
- 血浆代谢组学可强预测PD进展,15种基线血浆成分与UPDRS变化相关系数达0.87。
- 15种标志物中3种为黄嘌呤结构,4种为中或长链脂肪酸。
- 脑脊液多巴胺代谢物高香草酸变化小,与UPDRS恶化相关性弱(0.29,p=0.041)。
核心结论
- 血浆代谢组学分析能强预测帕金森病进展,并可能为PD发病机制提供新见解。
研究设计与样本
- 研究纳入49例未用药、轻度受累的帕金森病患者,平均年龄61.4岁,平均病程11.4个月。
- 在基线和最终(间隔最长24个月)两次采集血浆和脑脊液,检测小分子(≤1.5 kDa)成分。
- 采用超高效液相色谱串联气相色谱和质谱,经LASSO回归筛选与UPDRS第2+3部分评分变化相关的基线代谢物。
主要发现
- 随访期间UPDRS第2+3部分评分平均增加47%(从28.8到42.2)。
- LASSO从575种血浆和383种脑脊液生化物质中选出15种基线血浆成分,与UPDRS评分变化高度正相关(0.87,p=2.2e-16)。
- 15种标志物中3种为黄嘌呤结构,4种为中或长链脂肪酸。
- 通路富集软件未发现15种标志物在代谢通路中过度代表。
- 脑脊液高香草酸浓度基线至最终变化小,与UPDRS第2+3部分评分恶化相关性弱(0.29,p=0.041)。
临床怎么用
- 血浆代谢组学标志物有望用于预测帕金森病进展,辅助临床监测与分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether a Parkinson disease (PD)-specific biochemical signature might be found in the total body metabolic milieu or in the CSF compartment, especially since this disorder has systemic manifestations beyond the progressive loss of dopaminergic nigrostriatal neurons. METHODS: Our goal was to discover biomarkers of PD progression. Using ultra-high-performance liquid chromatography linked to gas chromatography and tandem mass spectrometry, we measured concentrations of small-molecule (≤1.5 kDa) constituents of plasma and CSF from 49 unmedicated, mildly affected patients with PD (mean age 61.4 years; mean duration of PD 11.4 months). Specimens were collected twice (baseline and final) at intervals up to 24 months. During this time, mean Unified Parkinson's Disease Rating Scale (UPDRS) parts 2 + 3 scores increased 47% (from 28.8 to 42.2). Measured compounds underwent unbiased univariate and multivariate analyses, including fitting data into multiple linear regression with variable selection using least absolute shrinkage and selection operator (LASSO). RESULTS: Of 575 identified plasma and 383 CSF biochemicals, LASSO led to selection of 15 baseline plasma constituents with high positive correlation (0.87, p = 2.2e-16) to baseline-to-final change in UPDRS parts 2 + 3 scores. Three of the compounds had xanthine structures, and 4 were either medium- or long-chain fatty acids. For the 15 LASSO-selected biomarkers, pathway enrichment software found no overrepresentation among metabolic pathways. CSF concentrations of the dopamine metabolite homovanillate showed little change between baseline and final collections and minimal correlation with worsening UPDRS parts 2 + 3 scores (0.29, p = 0.041). CONCLUSIONS: Metabolomic profiling of plasma yielded strong prediction of PD progression and offered biomarkers that may provide new insights into PD pathogenesis.
引用
- LeWitt PA, Li J, Lu M, et al. Metabolomic biomarkers as strong correlates of Parkinson disease progression. Neurology. 2017. PMID: 28179471. doi:10.1212/WNL.0000000000003663
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。